AMW Secures Successful Long-term Growth Financing from Raiffeisenlandesbank Oberösterreich
Warngau, Germany, July 24, 2025
AMW GmbH, a specialty pharmaceutical company focused on biodegradable controlled-release drug delivery systems, today announced the closing of a significant financing agreement. This long-term and attractive financing from Raiffeisenlandesbank Oberösterreich allowed the Company to optimize its financing structure and to gain access to an additional line of credit.
“With another record result for the 2024 financial year, based on a significant increase in revenues of 30%, we managed to reposition a considerable portion of our financing structure from a position of strength,” said Matthias Dittmer, Vice President Finance and IT at AMW. “The Company’s positive assessment from the financial markets is reflected in this successful growth financing. This underlines the confidence our financial partners hold in the stability and future viability of AMW. We are delighted to have entered bank financing with Raiffeisenlandesbank Oberösterreich.”
“The new financing agreement is an important milestone for AMW, enabling us to pursue our strategic goals with even greater stability and flexibility,” added Philipp Karbach, CEO and shareholder of AMW. “I would like to express my sincere thanks to all partners and colleagues involved in this project.”
AMW will use the additional liquid funds deriving from the refinancing to further pursue on its sustainable growth trajectory with a focus on its core business of developing, manufacturing and distribution of biodegradable controlled-release drug delivery systems. With two approved products on the market, AMW already provides patients in over 45 countries with drug delivery systems for improved adherence and cost-effective therapies.
###
About AMW GmbH:
AMW is a specialty pharmaceutical company focused on biodegradable implants, providing patients and partners access to value-added medicines for improved adherence and cost-effective therapies. The Company covers the entire value chain, from (co-)development to manufacturing and international commercialization.
AMW has two approved medical products: implants releasing goserelin or leuprorelin respectively, which are distributed worldwide via direct sales and out-licensing. In Germany, leuprorelin is marketed as Leugon® by AMW’s fully owned subsidiary Endomedica GmbH. Based on its unparalleled expertise in formulation development, the Company collaborates with pharma and biotech partners worldwide to develop and manufacture high-quality products and life-cycle solutions.
AMW is based in Warngau near Munich, Germany.
For further information please contact:
AMW GmbH
Eva Hoffmann
Phone: +49 8024 470999-0
E-mail: news@amw-pharmaceuticals.com